{"id":309,"date":"2026-02-18T16:25:17","date_gmt":"2026-02-18T14:25:17","guid":{"rendered":"http:\/\/example.test\/?post_type=product&#038;p=309"},"modified":"2026-09-10T10:19:39","modified_gmt":"2026-09-10T07:19:39","slug":"tirzepatide-10-mg","status":"publish","type":"product","link":"https:\/\/life-peptide.com\/cs\/product\/tirzepatide-10-mg\/","title":{"rendered":"Tirzepatid 10 mg"},"content":{"rendered":"<p><strong>Tirzepatid <\/strong><strong>10 mg in Europe | <\/strong><em>Chcete si v Evrop\u011b koupit tirzepatid? Spole\u010dnost Life Peptide dod\u00e1v\u00e1 tirzepatid vysok\u00e9 \u010distoty pro laboratorn\u00ed v\u00fdzkum a zaji\u0161\u0165uje spolehlivou dopravu po cel\u00e9 EU.<\/em><\/p>\n<h4><strong>Available in two formats<\/strong><\/h4>\n<p><em>Choose between a conventional lyophilized vial and a dual-chamber cartridge.<\/em><\/p>\n<p>The cartridge keeps Tirzepatide and its diluent in separate chambers until activation. This avoids transporting the peptide as a premixed solution and simplifies laboratory preparation by removing the separate liquid-transfer step. Final dual-chamber cartridge concentration: 10 mg in 1 mL. A compatible reusable device is required.<\/p>\n<hr \/>\n<p>Tirzepatide je du\u00e1ln\u00ed inkretinov\u00fd agonista ve v\u00fdzkumn\u00e9 kvalit\u011b dod\u00e1van\u00fd v lyofilizovan\u00e9 form\u011b pro laboratorn\u00ed pou\u017eit\u00ed. P\u016fsob\u00ed na <strong>oba receptory GLP-1 a GIP<\/strong> a stal se \u00fast\u0159edn\u00ed referen\u010dn\u00ed slou\u010deninou v metabolick\u00e9m v\u00fdzkumu, zejm\u00e9na v modelech <strong>regulace chuti k j\u00eddlu, zm\u011bna t\u011blesn\u00e9 hmotnosti, glykemick\u00e1 kontrola a inkretinov\u00e1 signalizace<\/strong>.<\/p>\n<p>Tirzepatid pat\u0159\u00ed do nov\u011bj\u0161\u00ed t\u0159\u00eddy zkouman\u00fdch metabolick\u00fdch peptid\u016f ur\u010den\u00fdch k vazb\u011b <strong>v\u00edce ne\u017e jedna inkretinov\u00e1 dr\u00e1ha sou\u010dasn\u011b<\/strong>, nam\u00edsto zam\u011b\u0159en\u00ed se pouze na GLP-1. Tento du\u00e1ln\u00ed receptorov\u00fd profil ho \u010din\u00ed obzvl\u00e1\u0161t\u011b relevantn\u00edm ve v\u00fdzkumu zam\u011b\u0159en\u00e9m na obezitu, gluk\u00f3zovou homeost\u00e1zu, inzul\u00ednovou signalizaci, energetickou rovnov\u00e1hu a metabolick\u00e1 terapeutika nov\u00e9 generace. Tirzepatid je dod\u00e1v\u00e1n jako lyofilizovan\u00e1 lahvi\u010dka pouze pro laboratorn\u00ed a analytick\u00e9 pou\u017eit\u00ed.<\/p>\n<hr \/>\n<h4><strong>Co je Tirzepatid?<\/strong><\/h4>\n<p>Tirzepatid je zkouman\u00fd <strong>agonista dvojit\u00e9ho inkretinov\u00e9ho receptoru<\/strong> navr\u017een\u00fd k aktivaci dvou kl\u00ed\u010dov\u00fdch receptorov\u00fdch syst\u00e9m\u016f zapojen\u00fdch do regulace metabolismu:<\/p>\n<ul>\n<li><strong>GLP-1 receptor<\/strong><\/li>\n<li><strong>GIP receptor<\/strong><\/li>\n<\/ul>\n<p>Tento receptorov\u00fd profil \u0159ad\u00ed Tirzepatid mezi <a href=\"https:\/\/life-peptide.com\/cs\/product\/semaglutide-10-mg\/\">Semaglutid <\/a>a <a href=\"https:\/\/life-peptide.com\/cs\/product\/retatrutide-10-mg\/\">Retatrutid<\/a> v mechanistick\u00e9 \u0161\u00ed\u0159i. Semaglutid c\u00edl\u00ed prim\u00e1rn\u011b pouze na GLP-1, zat\u00edmco Retatrutid p\u0159esahuje GLP-1\/GIP do <strong>agonismus glukagonov\u00e9ho receptoru<\/strong>. Tirzepatid zauj\u00edm\u00e1 st\u0159edn\u00ed postaven\u00ed: \u0161ir\u0161\u00ed ne\u017e klasick\u00e9 analogy GLP-1, ale selektivn\u011bj\u0161\u00ed ne\u017e trojit\u00e9 agonisty.<\/p>\n<p>D\u00edky tomuto postaven\u00ed se Tirzepatid stal jednou z nejd\u016fle\u017eit\u011bj\u0161\u00edch referen\u010dn\u00edch slou\u010denin v sou\u010dasn\u00e9m metabolick\u00e9m v\u00fdzkumu. Je \u0161iroce pou\u017e\u00edv\u00e1n jako srovn\u00e1vac\u00ed bod ve studi\u00edch zkoumaj\u00edc\u00edch <strong>strategie vyu\u017e\u00edvaj\u00edc\u00ed jeden, dva nebo t\u0159i typy incretinov\u00fdch receptor\u016f<\/strong>. Lilly a recenzovan\u00e1 klinick\u00e1 literatura konzistentn\u011b popisuj\u00ed Tirzepatid jako <strong>jednou t\u00fddn\u011b du\u00e1ln\u00ed GIP\/GLP-1 receptorov\u00fd agonista<\/strong> se siln\u00fdmi \u00fa\u010dinky na v\u00fdsledky glyk\u00e9mie a t\u011blesn\u00e9 hmotnosti v klinick\u00fdch studi\u00edch u lid\u00ed.<\/p>\n<h4><strong>Pro\u010d je tirzepatid d\u016fle\u017eit\u00fd v metabolick\u00e9m v\u00fdzkumu<\/strong><\/h4>\n<p>Tirzepatid je d\u016fle\u017eit\u00fd, proto\u017ee kombinuje signalizaci GLP-1 s aktivitou GIP receptoru, \u010d\u00edm\u017e vytv\u00e1\u0159\u00ed \u0161ir\u0161\u00ed inkretinov\u00fd profil ne\u017e samotn\u00ed agonist\u00e9 GLP-1, p\u0159i\u010dem\u017e z\u016fst\u00e1v\u00e1 v\u00edce zam\u011b\u0159en\u00fd ne\u017e trojn\u00ed agonist\u00e9, jako je Retatrutid.<\/p>\n<p>V literatu\u0159e byl tirzepatid studov\u00e1n v souvislosti s:<\/p>\n<ul>\n<li>regulace t\u011blesn\u00e9 hmotnosti a signalizace chuti k j\u00eddlu<\/li>\n<li>metabolismus gluk\u00f3zy a glykemick\u00e9 markery<\/li>\n<li>inzulinov\u00e1 signalizace a zpracov\u00e1n\u00ed \u017eivin<\/li>\n<li>energetick\u00e1 rovnov\u00e1ha a syst\u00e9mov\u00e1 metabolick\u00e1 regulace<\/li>\n<li>srovn\u00e1vac\u00ed inkretinov\u00fd v\u00fdzkum u model\u016f GLP-1, du\u00e1ln\u00edch agonist\u016f a trojit\u00fdch agonist\u016f<\/li>\n<\/ul>\n<p>Pro v\u00fdzkumn\u00edky, kte\u0159\u00ed vytv\u00e1\u0159ej\u00ed panel metabolick\u00fdch peptid\u016f, Tirzepatid \u010dasto slou\u017e\u00ed jako centr\u00e1ln\u00ed srovn\u00e1vac\u00ed molekula mezi Semaglutidem a Retatrutidem. Je to jeden z nejjasn\u011bj\u0161\u00edch p\u0159\u00edklad\u016f toho, jak roz\u0161\u00ed\u0159en\u00ed z jednocestn\u00e9ho agonistu GLP-1 na du\u00e1ln\u00ed inkretinov\u00fd agonista m\u016f\u017ee zm\u011bnit zkouman\u00fd metabolick\u00fd profil. Va\u0161e sou\u010dasn\u00e1 str\u00e1nka ji\u017e sm\u011b\u0159uje t\u00edmto sm\u011brem; rozd\u00edl spo\u010d\u00edv\u00e1 v tom, \u017ee logiku srovn\u00e1n\u00ed a vyhled\u00e1vac\u00ed plochu \u010din\u00edme mnohem explicitn\u011bj\u0161\u00ed.<\/p>\n<h4><strong>Jak funguje Tirzepatid<\/strong><\/h4>\n<p>Tirzepatid je navr\u017een tak, aby aktivoval dva receptorov\u00e9 syst\u00e9my zapojen\u00e9 do metabolick\u00e9 regulace.<\/p>\n<p><strong>Aktivita GLP-1 receptoru<\/strong><\/p>\n<p>Signalizace GLP-1 je spojena se sn\u00ed\u017een\u00edm chuti k j\u00eddlu, opo\u017ed\u011bn\u00fdm vyprazd\u0148ov\u00e1n\u00edm \u017ealudku a podporou inzul\u00ednu z\u00e1vislou na gluk\u00f3ze. To je dr\u00e1ha, kterou v\u011bt\u0161ina v\u00fdzkumn\u00edk\u016f ji\u017e zn\u00e1 z l\u00e1tek, jako je semaglutid.<\/p>\n<p><strong>Aktivita GIP receptoru<\/strong><\/p>\n<p>Sign\u00e1lov\u00e1n\u00ed GIP je pova\u017eov\u00e1no za vliv na sekreci inzul\u00ednu, zpracov\u00e1n\u00ed \u017eivin, metabolismus tukov\u00e9 tk\u00e1n\u011b a celkovou inkretinovou odpov\u011b\u010f na p\u0159\u00edjem potravy. Ve v\u00fdzkumu du\u00e1ln\u00edch agonist\u016f je aktivita GIP jedn\u00edm z hlavn\u00edch d\u016fvod\u016f, pro\u010d je Tirzepatid mechanisticky \u0161ir\u0161\u00ed ne\u017e slou\u010deniny pouze s GLP-1.<\/p>\n<p><strong>Du\u00e1ln\u00ed inkretinov\u00fd profil<\/strong><\/p>\n<p>Kombinace aktivity GLP-1 a GIP d\u00e1v\u00e1 Tirzepatidu odli\u0161n\u00fd metabolick\u00fd profil od Semaglutidu i Retatrutidu. Ve srovn\u00e1n\u00ed se Semaglutidem roz\u0161i\u0159uje rozsah signalizace nad r\u00e1mec samotn\u00e9ho GLP-1. Ve srovn\u00e1n\u00ed s Retatrutidem z\u016fst\u00e1v\u00e1 selektivn\u011bj\u0161\u00ed, proto\u017ee nezahrnuje agonismus glukagonov\u00e9ho receptoru.<\/p>\n<p>D\u00edky tomu je Tirzepatid obzvl\u00e1\u0161t\u011b u\u017eite\u010dn\u00fd ve v\u00fdzkumu zam\u011b\u0159en\u00e9m na:<\/p>\n<ul>\n<li><strong>GLP-1 vs du\u00e1ln\u00ed agonist\u00e9 \u2013 porovn\u00e1n\u00ed<\/strong><\/li>\n<li><strong>t\u011blesn\u00e1 hmotnost a v\u00fdsledky chuti k j\u00eddlu<\/strong><\/li>\n<li><strong>homeost\u00e1za gluk\u00f3zy a dynamika inzulinu<\/strong><\/li>\n<li><strong>p\u0159echod od jednocestn\u00e9 k v\u00edcecestn\u00e9 inkretinov\u00e9 modulaci<\/strong><\/li>\n<\/ul>\n<hr \/>\n<h4><strong>Publikovan\u00e9 klinick\u00e9 n\u00e1lezy na tirzepatid<\/strong><\/h4>\n<p>Tirzepatid se stal jedn\u00edm z nejv\u00edce sledovan\u00fdch metabolick\u00fdch peptid\u016f, proto\u017ee publikovan\u00e9 studie na lidech hl\u00e1s\u00ed <strong>v\u00fdznamn\u00e9 \u00fa\u010dinky na t\u011blesnou hmotnost, glykemickou kontrolu a \u0161ir\u0161\u00ed kardiometabolick\u00e9 ukazatele<\/strong>. V klinick\u00e9 studii SURMOUNT-1 publikovan\u00e9 v <em>New England Journal of Medicine<\/em>, jednou t\u00fddn\u011b pod\u00e1van\u00fd tirzepatid vyvolal <strong>d\u00e1vkov\u011b z\u00e1visl\u00e9 sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti<\/strong> v\u00edce ne\u017e 72 t\u00fddn\u016f u dosp\u011bl\u00fdch s obezitou nebo nadv\u00e1hou, p\u0159i\u010dem\u017e rameno s nejvy\u0161\u0161\u00ed d\u00e1vkou vykazovalo n\u011bkter\u00e9 z nejsiln\u011bj\u0161\u00edch v\u00fdsledk\u016f hubnut\u00ed hl\u00e1\u0161en\u00fdch v t\u00e9 dob\u011b u terapie zalo\u017een\u00e9 na inkretinech.<\/p>\n<p>Tirzepatid tak\u00e9 prok\u00e1zal siln\u00e9 glykemick\u00e9 \u00fa\u010dinky ve v\u00fdzkumu diabetu 2. typu. Ve studii SURPASS-2 byl tirzepatid p\u0159\u00edmo porovn\u00e1n s jednou t\u00fddenn\u00ed d\u00e1vkou semaglutidu a prok\u00e1zal <strong>v\u011bt\u0161\u00ed sn\u00ed\u017een\u00ed HbA1c a v\u011bt\u0161\u00ed sn\u00ed\u017een\u00ed hmotnosti<\/strong> nap\u0159\u00ed\u010d zkouman\u00fdmi d\u00e1vkovac\u00edmi rameny. Dal\u0161\u00ed studie SURPASS d\u00e1le etablovaly tirzepatid jako jednoho z kl\u00ed\u010dov\u00fdch du\u00e1ln\u00edch agonist\u016f v sou\u010dasn\u00e9 metabolick\u00e9 literatu\u0159e. Va\u0161e sou\u010dasn\u00e1 str\u00e1nka ji\u017e cituje nejd\u016fle\u017eit\u011bj\u0161\u00ed studie \u2013 SURMOUNT-1, SURPASS-2 a souvisej\u00edc\u00ed pr\u00e1ce o diabetu \u2013 co\u017e je pro tuto sekci naprosto spr\u00e1vn\u00fd d\u016fkazn\u00ed z\u00e1klad.<\/p>\n<p>Tyto studie dohromady jsou hlavn\u00edm d\u016fvodem, pro\u010d je tirzepatid tak \u010dasto pou\u017e\u00edv\u00e1n jako referen\u010dn\u00ed bod v modern\u00edm v\u00fdzkumu obezity a diabetu. Nach\u00e1z\u00ed se v centru srovn\u00e1n\u00ed mezi <strong>Agonist\u00e9 GLP-1, du\u00e1ln\u00ed agonist\u00e9 GLP-1\/GIP a nov\u011bj\u0161\u00ed trojit\u00fd agonista<\/strong> p\u0159\u00edstupy.<\/p>\n<table>\n<thead>\n<tr>\n<th>Studie<\/th>\n<th>Populace<\/th>\n<th align=\"right\">Doba trv\u00e1n\u00ed<\/th>\n<th>Hlavn\u00ed publikovan\u00e9 v\u00fdsledky<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>SURMOUNT-1<\/strong><\/td>\n<td>Dosp\u011bl\u00ed s obezitou nebo nadv\u00e1hou bez diabetu<\/td>\n<td align=\"right\">72 t\u00fddn\u016f<\/td>\n<td>Pr\u016fm\u011brn\u00e1 zm\u011bna t\u011blesn\u00e9 hmotnosti byla <strong>\u221215,01 TP3T, \u221219,51 TP3T a \u221220,91 TP3T<\/strong> s d\u00e1vkami 5, 10 a 15 mg tirzepatidu, zat\u00edmco u placeba to bylo \u22123,11 TP3T.<\/td>\n<\/tr>\n<tr>\n<td><strong>SURPASS-2<\/strong><\/td>\n<td>Dosp\u011bl\u00ed s diabetes 2. typu<\/td>\n<td align=\"right\">40 t\u00fddn\u016f<\/td>\n<td>HbA1c klesl o <strong>\u22122,01%, \u22122,24% a \u22122,30%<\/strong> u tirzepatidu v d\u00e1vk\u00e1ch 5, 10 a 15 mg oproti \u22121,86% u semaglutidu v d\u00e1vce 1 mg. Tirzepatid rovn\u011b\u017e vedl k v\u011bt\u0161\u00edmu pr\u016fm\u011brn\u00e9mu sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti ve v\u0161ech t\u0159ech d\u00e1vkov\u00fdch skupin\u00e1ch.<\/td>\n<\/tr>\n<tr>\n<td><strong>SURPASS-3<\/strong><\/td>\n<td>Dosp\u011bl\u00ed s diabetes mellitus 2. typu nedostate\u010dn\u011b pod kontrolou peror\u00e1ln\u00ed terapi\u00ed<\/td>\n<td align=\"right\">52 t\u00fddn\u016f<\/td>\n<td>Tirzepatid vedl k v\u00fdrazn\u011bj\u0161\u00edmu sn\u00ed\u017een\u00ed hodnot HbA1c a t\u011blesn\u00e9 hmotnosti ne\u017e insulin degludec ve v\u0161ech sledovan\u00fdch d\u00e1vkov\u00fdch skupin\u00e1ch.<\/td>\n<\/tr>\n<tr>\n<td><strong>program SURPASS<\/strong><\/td>\n<td>Dosp\u011bl\u00ed s diabetem 2. typu v mnoha klinick\u00fdch studi\u00edch f\u00e1ze 3<\/td>\n<td align=\"right\">40\u2013104 t\u00fddn\u016f<\/td>\n<td>\u0160ir\u0161\u00ed program prok\u00e1zal konzistentn\u00ed \u00fa\u010dinky na glykemickou kontrolu a t\u011blesnou hmotnost z\u00e1visl\u00e9 na d\u00e1vce nap\u0159\u00ed\u010d r\u016fzn\u00fdmi srovn\u00e1vac\u00edmi l\u00e9\u010dbami a populacemi pacient\u016f.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>D\u016fle\u017eit\u00e9<\/strong>V\u00fdsledky zobrazen\u00e9 v\u00fd\u0161e shrnuj\u00ed publikovan\u00e9 klinick\u00e9 studie farmaceutick\u00e9ho p\u0159\u00edpravku Tirzepatid a jsou poskytnuty pouze jako v\u00fdzkumn\u00fd kontext. Nem\u011bly by b\u00fdt interpretov\u00e1ny jako o\u010dek\u00e1van\u00e9 v\u00fdsledky tohoto v\u00fdzkumn\u00e9ho produktu.<\/p>\n<hr \/>\n<h4><strong>Publikovan\u00e9 v\u00fdsledky t\u00fdkaj\u00edc\u00ed se bezpe\u010dnosti a sn\u00e1\u0161enlivosti<\/strong><\/h4>\n<p>Publikovan\u00e9 klinick\u00e9 studie o tirzepatidu nazna\u010duj\u00ed, \u017ee nej\u010dast\u011bji hl\u00e1\u0161en\u00fdmi ne\u017e\u00e1douc\u00edmi \u00fa\u010dinky jsou gastrointestin\u00e1ln\u00ed, zejm\u00e9na <strong>nevolnost, pr\u016fjem, sn\u00ed\u017een\u00e1 chu\u0165 k j\u00eddlu, zvracen\u00ed a z\u00e1cpa<\/strong>. Stejn\u011b jako u jin\u00fdch inkretinov\u00fdch p\u0159\u00edpravk\u016f byly tyto p\u0159\u00edhody obecn\u011b \u010dast\u011bj\u0161\u00ed ne\u017e u placeba a byly \u010dasto <strong>d\u00e1vkov\u011b z\u00e1visl\u00fd<\/strong>, zejm\u00e9na b\u011bhem f\u00e1ze eskalace d\u00e1vky l\u00e9\u010dby.<\/p>\n<p>Nap\u0159\u00ed\u010d hlavn\u00edmi klinick\u00fdmi programy bylo v\u011bt\u0161in\u011b gastrointestin\u00e1ln\u00edch p\u0159\u00edhod pops\u00e1no jako <strong>m\u00edrn\u00fd a\u017e st\u0159edn\u00ed<\/strong> z\u00e1va\u017enosti a m\u00edra p\u0159eru\u0161en\u00ed l\u00e9\u010dby st\u00e1le tvo\u0159ily d\u016fle\u017eitou sou\u010d\u00e1st hodnocen\u00ed celkov\u00e9ho profilu Tirzepatidu. To je jeden z d\u016fvod\u016f, pro\u010d se publikovan\u00e9 v\u00fdzkumy Tirzepatidu obvykle diskutuj\u00ed nejen z hlediska \u00fa\u010dinnosti, ale tak\u00e9 z hlediska <strong>sn\u00e1\u0161enlivost b\u011bhem eskalace<\/strong>, z\u00e1t\u011b\u017e spojen\u00e1 s gastrointestin\u00e1ln\u00edmi p\u0159\u00edhodami a rovnov\u00e1ha mezi metabolick\u00fdm p\u0159\u00ednosem a rizikem p\u0159eru\u0161en\u00ed l\u00e9\u010dby.<\/p>\n<p>Tato sekce shrnuje <strong>publikovan\u00e9 poznatky o zkouman\u00e9m a klinick\u00e9m v\u00fdzkumu Tirzepatidu<\/strong>, nikoli pokyny nebo o\u010dek\u00e1v\u00e1n\u00ed t\u00fdkaj\u00edc\u00ed se pou\u017eit\u00ed tohoto produktu.<\/p>\n<h4><strong>Publikovan\u00e9 d\u00e1vkovac\u00ed sch\u00e9my pou\u017e\u00edvan\u00e9 ve v\u00fdzkumu tirzepatidu<\/strong><\/h4>\n<p>Publikovan\u00e9 studie o tirzepatidu obecn\u011b pou\u017e\u00edvaly <strong>pod\u00e1v\u00e1n\u00ed jednou t\u00fddn\u011b s postupn\u00fdm zvy\u0161ov\u00e1n\u00edm d\u00e1vky<\/strong> m\u00edsto aby se ihned za\u010d\u00ednalo na kone\u010dn\u00e9 c\u00edlov\u00e9 d\u00e1vce. V hlavn\u00edch studi\u00edch obezity a diabetu byl tirzepatid typicky zkoum\u00e1n v d\u00e1vce <strong>5 mg, 10 mg a 15 mg udr\u017eovac\u00edch d\u00e1vek<\/strong>, s eskalac\u00ed z ni\u017e\u0161\u00ed po\u010d\u00e1te\u010dn\u00ed d\u00e1vky v pr\u016fb\u011bhu n\u011bkolika t\u00fddn\u016f pro zlep\u0161en\u00ed sn\u00e1\u0161enlivosti. V\u00e1\u0161 aktu\u00e1ln\u00ed seznam referenc\u00ed ji\u017e odkazuje na kl\u00ed\u010dov\u00e9 studie, kter\u00e9 tuto strukturu zavedly.<\/p>\n<p>Z praktick\u00e9ho hlediska je zve\u0159ejn\u011bn\u00fd v\u00fdzkumn\u00fd pl\u00e1n pro tirzepatid d\u016fle\u017eit\u00fd, proto\u017ee ukazuje, \u017ee <strong>\u00da\u010dinnost a sn\u00e1\u0161enlivost byly zkoum\u00e1ny spole\u010dn\u011b<\/strong>. V\u00fdzkumn\u00edci netestovali jednodu\u0161e \u201cjednu d\u00e1vku Tirzepatidu\u201d; testovali postupn\u00e9 eskaluj\u00edc\u00ed strategie vedouc\u00ed k r\u016fzn\u00fdm udr\u017eovac\u00edm d\u00e1vk\u00e1m. To je jeden z d\u016fvod\u016f, pro\u010d Tirzepatid z\u016fst\u00e1v\u00e1 tak u\u017eite\u010dnou srovn\u00e1vac\u00ed slou\u010deninou ve v\u00fdzkumu metabolick\u00fdch peptid\u016f.<\/p>\n<p><strong>P\u0159\u00edklad struktury udr\u017eovac\u00ed d\u00e1vky b\u011b\u017en\u011b pou\u017e\u00edvan\u00fd v hlavn\u00edch studi\u00edch<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Kontext zve\u0159ejn\u011bn\u00e9 studie<\/th>\n<th align=\"right\">Po\u010d\u00e1te\u010dn\u00ed d\u00e1vkovac\u00ed p\u0159\u00edstup v klinick\u00e9 studii<\/th>\n<th align=\"right\">Podstudovan\u00e9 d\u00e1vky pro udr\u017eovac\u00ed l\u00e9\u010dbu<\/th>\n<th align=\"right\">Frekvence<\/th>\n<th align=\"right\">Doba trv\u00e1n\u00ed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Klinick\u00e9 studie obezity \/ diabetu<\/td>\n<td align=\"right\">postupn\u00e9 zvy\u0161ov\u00e1n\u00ed z ni\u017e\u0161\u00ed po\u010d\u00e1te\u010dn\u00ed d\u00e1vky<\/td>\n<td align=\"right\">5 mg<\/td>\n<td align=\"right\">jednou t\u00fddn\u011b<\/td>\n<td align=\"right\">li\u0161\u00ed se pokusem<\/td>\n<\/tr>\n<tr>\n<td>Klinick\u00e9 studie obezity \/ diabetu<\/td>\n<td align=\"right\">postupn\u00e9 zvy\u0161ov\u00e1n\u00ed z ni\u017e\u0161\u00ed po\u010d\u00e1te\u010dn\u00ed d\u00e1vky<\/td>\n<td align=\"right\">10 mg<\/td>\n<td align=\"right\">jednou t\u00fddn\u011b<\/td>\n<td align=\"right\">li\u0161\u00ed se pokusem<\/td>\n<\/tr>\n<tr>\n<td>Klinick\u00e9 studie obezity \/ diabetu<\/td>\n<td align=\"right\">postupn\u00e9 zvy\u0161ov\u00e1n\u00ed z ni\u017e\u0161\u00ed po\u010d\u00e1te\u010dn\u00ed d\u00e1vky<\/td>\n<td align=\"right\">15 mg<\/td>\n<td align=\"right\">jednou t\u00fddn\u011b<\/td>\n<td align=\"right\">li\u0161\u00ed se pokusem<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Tyto rozvrhy jsou zahrnuty jako souhrn publikovan\u00e9ho n\u00e1vrhu v\u00fdzkumu a nejsou pokyny k pou\u017eit\u00ed tohoto produktu.<\/strong><\/p>\n<hr \/>\n<h4><strong>Tirzepatid vs. Semaglutid vs. Retatrutid<\/strong><\/h4>\n<p>V\u00fdzkumn\u00edci \u010dasto porovn\u00e1vaj\u00ed tyto t\u0159i slou\u010deniny, proto\u017ee se nach\u00e1zej\u00ed na stejn\u00e9m metabolick\u00e9m spektru, ale nejsou zam\u011bniteln\u00e9.<\/p>\n<p><strong>Tirzepatid<\/strong><\/p>\n<ul>\n<li><strong>Du\u00e1ln\u00ed agonista<\/strong>GLP-1 + GIP<\/li>\n<li>Centr\u00e1ln\u00ed benchmark pro v\u00fdzkum du\u00e1ln\u00edch inkretin\u016f<\/li>\n<li>\u010casto diskutov\u00e1no v souvislosti s <strong>v\u00fdsledky t\u011blesn\u00e9 hmotnosti, glykemick\u00e1 kontrola a inkretinov\u00e1 signalizace<\/strong><\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/life-peptide.com\/cs\/product\/semaglutide-10-mg\/\">Semaglutid<\/a><\/strong><\/p>\n<ul>\n<li><strong>Jedin\u00fd agonista<\/strong>GLP-1<\/li>\n<li>V\u00fdb\u011brov\u011bj\u0161\u00ed a mechanisticky u\u017e\u0161\u00ed<\/li>\n<li>Spole\u010dn\u00fd referen\u010dn\u00ed bod pro <strong>V\u00fdzkum dr\u00e1hy GLP-1<\/strong><\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/life-peptide.com\/cs\/product\/retatrutide-10-mg\/\">Retatrutid<\/a><\/strong><\/p>\n<ul>\n<li><strong>Trojit\u00fd agonista<\/strong>GLP-1 + GIP + glukagon<\/li>\n<li>\u0160ir\u0161\u00ed profil receptor\u016f ne\u017e Tirzepatid<\/li>\n<li>\u010casto diskutov\u00e1no v souvislosti s <strong>redukce hmotnosti, v\u00fddej energie a v\u00edcekan\u00e1lov\u00e1 metabolick\u00e1 modulace nov\u00e9 generace<\/strong><\/li>\n<\/ul>\n<p>Podrobn\u00e9 srovn\u00e1n\u00ed aktivity receptor\u016f, publikovan\u00fdch klinick\u00fdch zji\u0161t\u011bn\u00ed a v\u00fdzkumn\u00fdch rozd\u00edl\u016f si m\u016f\u017eete p\u0159e\u010d\u00edst v na\u0161em <a href=\"https:\/\/life-peptide.com\/cs\/retatrutide-vs-tirzepatide\/\">Porovn\u00e1n\u00ed v\u00fdzkumu retatrutidu a tirzepatidu<\/a>.<\/p>\n<p>Pro v\u00fdzkumn\u00edky porovn\u00e1vaj\u00edc\u00ed t\u0159\u00eddy inkretin\u016f \u010dasto Tirzepatid slou\u017e\u00ed jako <strong>st\u0159edn\u00ed referen\u010dn\u00ed bod<\/strong> mezi jednocestn\u00fdmi agonisty GLP-1 a \u0161ir\u0161\u00edmi trojit\u00fdmi agonisty.<\/p>\n<hr \/>\n<h4><strong>Vlastnosti produktu<\/strong><\/h4>\n<p>Aplikace: laboratorn\u00ed a analytick\u00fd v\u00fdzkum<br \/>\nPou\u017eit\u00ed omezen\u00e9: nen\u00ed ur\u010deno k lidsk\u00e9 spot\u0159eb\u011b; pro l\u00e9ka\u0159sk\u00e9, veterin\u00e1rn\u00ed ani kosmetick\u00e9 pou\u017eit\u00ed<br \/>\nVyrobeno v za\u0159\u00edzen\u00edch spl\u0148uj\u00edc\u00edch spr\u00e1vnou v\u00fdrobn\u00ed praxi (GMP) za p\u0159\u00edsn\u00fdch protokol\u016f kontroly kvality.<br \/>\nKa\u017ed\u00e1 \u0161ar\u017ee je po v\u00fdrob\u011b pe\u010dliv\u011b laboratorn\u011b testov\u00e1na (Certifik\u00e1t o anal\u00fdze najdete pod obr\u00e1zky produkt\u016f).<br \/>\nLyofilizov\u00e1no (su\u0161eno mrazem) pro maxim\u00e1ln\u00ed stabilitu a prodlou\u017eenou trvanlivost.<br \/>\nUzav\u0159eno ve steriln\u00edch lahvi\u010dk\u00e1ch, p\u0159ipraveno k rekonstituci.<br \/>\n\u010cistota: \u226599% (testov\u00e1no metodou HPLC)<br \/>\nVzhled: Lyofilizovan\u00fd b\u00edl\u00fd\/neb\u00edle b\u00edl\u00fd pr\u00e1\u0161ek<br \/>\nMolekul\u00e1rn\u00ed vzorec: C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub><br \/>\nMolekulov\u00e1 hmotnost: 4813,45<br \/>\nTyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-\u03b3-Glu-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2<br \/>\n<strong>\u00dalo\u017ei\u0161t\u011b<\/strong>Neotev\u0159en\u00e9 lyofilizovan\u00e9 lahvi\u010dky jsou nejl\u00e9pe skladov\u00e1ny <strong>chlazen\u00e9 p\u0159i 2\u20138 \u00b0C<\/strong>, co\u017e je metoda skladov\u00e1n\u00ed potvrzen\u00e1 na\u0161\u00edm v\u00fdrobn\u00edm partnerem a vhodn\u00e1 a\u017e po dobu 24 m\u011bs\u00edc\u016f. Preferuje se chlazen\u00ed, proto\u017ee minimalizuje zbyte\u010dn\u00e9 cykly zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed b\u011bhem b\u011b\u017en\u00e9 manipulace. Pokud je vy\u017eadov\u00e1no podstatn\u011b del\u0161\u00ed skladov\u00e1n\u00ed, lze zmrazen\u00e9 uchov\u00e1vat i neotev\u0159en\u00e9 lyofilizovan\u00e9 lahvi\u010dky. Po rekonstituci v\u017edy skladujte p\u0159i 2\u20138 \u00b0C a nezmrazujte.<\/p>\n<h4><strong>Nez\u00e1visl\u00e9 ov\u011b\u0159en\u00ed t\u0159et\u00ed stranou<\/strong><\/h4>\n<p>Tato \u0161ar\u017ee pro\u0161la dodate\u010dn\u00fdm analytick\u00fdm ov\u011b\u0159en\u00edm t\u0159et\u00ed stranou prost\u0159ednictv\u00edm spole\u010dnosti Janoshik Analytical<br \/>\nD\u00e1vka: TR10-260423<br \/>\n\u010cistota stanoven\u00e1 intern\u00ed HPLC: 99,13%<br \/>\nOv\u011b\u0159en\u00ed t\u0159et\u00ed stranou: Spole\u010dnost 99.62% nez\u00e1visle potvrdila vysokou \u010distotu a shodu slo\u017een\u00ed. <a href=\"https:\/\/verify.janoshik.com\/tests\/166500-Tirzepatide_HZQXE7RE4JKV\" target=\"_blank\" rel=\"noopener\">Zobrazit ov\u011b\u0159en\u00ed t\u0159et\u00ed stranou<\/a>.<\/p>\n<h4><strong>Rekonstituce a manipulace<\/strong><\/h4>\n<p>Tirzepatid je dod\u00e1v\u00e1n jako lyofilizovan\u00e1 lahvi\u010dka a s p\u0159\u00edpravkem by m\u011blo b\u00fdt nakl\u00e1d\u00e1no za pou\u017eit\u00ed standardn\u00edch postup\u016f rekonstituce peptid\u016f vhodn\u00fdch pro v\u00fdzkumn\u00e9 prost\u0159ed\u00ed. Mus\u00ed b\u00fdt rekonstituov\u00e1n pomoc\u00ed <a href=\"https:\/\/life-peptide.com\/cs\/product\/bac-10-ml\/\">bakteriostatick\u00e1 voda<\/a> p\u0159ed pou\u017eit\u00edm. Peptidy t\u0159\u00eddy GLP-1 se n\u011bkdy rozpou\u0161t\u011bj\u00ed pomalu a vy\u017eaduj\u00ed velmi jemn\u00e9 rozpou\u0161t\u011bn\u00ed, aby se zabr\u00e1nilo p\u011bn\u011bn\u00ed nebo vzniku m\u00edrn\u00e9ho z\u00e1kalu.<\/p>\n<p>Pro dal\u0161\u00ed pokyny k v\u00fdb\u011bru rozpou\u0161t\u011bdla, pl\u00e1nov\u00e1n\u00ed koncentrac\u00ed a skladov\u00e1n\u00ed viz \u00fapln\u00e9 <a href=\"https:\/\/life-peptide.com\/cs\/reconstitution-of-peptides\/\">Pr\u016fvodce rekonstituc\u00ed peptid\u016f<\/a> a <a href=\"https:\/\/life-peptide.com\/cs\/calculator\/\">Kalkula\u010dka rekonstituce<\/a>.<\/p>\n<hr \/>\n<h4>Vybran\u00e9 v\u00fdzkumn\u00e9 reference<\/h4>\n<ul>\n<li>Jastreboff AM a kol. <em>\u201cTirzepatid jednou t\u00fddn\u011b k l\u00e9\u010db\u011b obezity.\u201d New England Journal of Medicine<\/em>, 2022.<\/li>\n<li>Frias JP a kol. <em>\u201cTirzepatid versus semaglutid jednou t\u00fddn\u011b u pacient\u016f s diabetes mellitus 2. typu. New England Journal of Medicine<\/em>, 2021.<\/li>\n<li>Ludv\u00edk B a kol. <em>\u201cTirzepatid jednou t\u00fddn\u011b versus insulin degludec jednou denn\u011b jako p\u0159\u00eddatn\u00e1 l\u00e9\u010dba k metforminu. The Lancet<\/em>, 2021.<\/li>\n<li>Coskun T a kol. <em>\u201cLY3298176, nov\u00fd du\u00e1ln\u00ed agonist\u00e9 receptor\u016f pro GIP a GLP-1 k l\u00e9\u010db\u011b diabetes mellitus 2. typu.\u201d Molecular Metabolism,<\/em> 2018.<\/li>\n<\/ul>\n<hr \/>\n<h4><strong>\u010casto kladen\u00e9 ot\u00e1zky<\/strong><\/h4>\n<p><strong>O jak\u00fd druh peptidu se jedn\u00e1 o tirzepatid?<\/strong><\/p>\n<p>Tirzepatid je zkou\u0161en\u00fd du\u00e1ln\u00ed agonist inkretin\u016f navr\u017een\u00fd k aktivaci receptor\u016f GLP-1 a GIP.<\/p>\n<p><strong>Jak se Tirzepatid li\u0161\u00ed od Semaglutidu?<\/strong><\/p>\n<p>Semaglutide prim\u00e1rn\u011b c\u00edl\u00ed pouze na GLP-1, zat\u00edmco tirzepatid kombinuje aktivitu receptor\u016f GLP-1 a GIP, co\u017e mu d\u00e1v\u00e1 \u0161ir\u0161\u00ed profil inkretinov\u00e9 sign\u00e1ln\u00ed dr\u00e1hy.<\/p>\n<p><strong>Jak se Tirzepatid li\u0161\u00ed od Retatrutidu?<\/strong><\/p>\n<p>Retatrutid je trojit\u00fd agonista, kter\u00fd k profilu GLP-1\/GIP p\u0159id\u00e1v\u00e1 aktivitu glukagonov\u00e9ho receptoru. Tirzepatid z\u016fst\u00e1v\u00e1 selektivn\u011bj\u0161\u00ed jako du\u00e1ln\u00ed agonista GLP-1\/GIP.<\/p>\n<p><strong>S jak\u00fdmi v\u00fdzkumn\u00fdmi oblastmi je tirzepatid spojov\u00e1n?<\/strong><\/p>\n<p>Tirzepatid byl v odborn\u00e9 literatu\u0159e studov\u00e1n ve vztahu k v\u00fdsledk\u016fm t\u011blesn\u00e9 hmotnosti, regulaci chuti k j\u00eddlu, glykemick\u00e9 kontrole, inzul\u00ednov\u00e9 signalizaci a biologii inkretin\u016f.<\/p>\n<p><strong>Jak tirzepatid funguje?<\/strong><\/p>\n<p>Tirzepatid sou\u010dasn\u011b aktivuje GIP a GLP-1 receptory. Tyto inkretinov\u00e9 dr\u00e1hy ovliv\u0148uj\u00ed na gluk\u00f3ze z\u00e1vislou sekreci inzul\u00ednu, regulaci chuti k j\u00eddlu, zpracov\u00e1n\u00ed \u017eivin a energetickou bilanci. Jeho aktivita na dvou receptech odli\u0161uje tirzepatid od l\u00e1tek obsahuj\u00edc\u00edch pouze GLP-1, jako je semaglutid. FDA popisuje tirzepatid jako selektivn\u011b se v\u00e1\u017e\u00edc\u00ed a aktivuj\u00edc\u00ed GIP i GLP-1 receptory.<\/p>\n<p><strong>Co zjistila studie SURMOUNT-1 s tirzepatidem?<\/strong><\/p>\n<p>Ve studii SURMOUNT-1 \u010dinilo pr\u016fm\u011brn\u00e9 sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti po 72 t\u00fddnech 15,0%, 19,51 TP3T a 20,91 TP3T u skupin s d\u00e1vkami 5 mg, 10 mg a 15 mg, zat\u00edmco u placeba \u010dinil \u00fabytek 3,11 TP3T. Do studie byli za\u0159azeni dosp\u011bl\u00ed s obezitou nebo nadv\u00e1hou bez diabetu.<\/p>\n<p><strong>Byl tirzepatid porovn\u00e1n p\u0159\u00edmo se semaglutidem?<\/strong><\/p>\n<p>Ano. Studie f\u00e1ze 3 SURPASS-2 p\u0159\u00edmo porovn\u00e1vala tirzepatid s <a href=\"https:\/\/life-peptide.com\/cs\/product\/semaglutide-10-mg\/\">Semaglutid<\/a> 1 mg u dosp\u011bl\u00fdch s diabetes mellitus 2. typu. Tirzepatid vyvolal v\u011bt\u0161\u00ed sn\u00ed\u017een\u00ed hladiny HbA1c a t\u011blesn\u00e9 hmotnosti nap\u0159\u00ed\u010d zkouman\u00fdmi d\u00e1vkami b\u011bhem 40t\u00fddenn\u00ed studie.<\/p>\n<p><strong>Jak by m\u011bl b\u00fdt lyofilizovan\u00fd tirzepatid uchov\u00e1v\u00e1n?<\/strong><\/p>\n<p>Pro tento v\u00fdzkumn\u00fd produkt je nejlep\u0161\u00ed uchov\u00e1vat neotev\u0159en\u00e9 lyofilizovan\u00e9 lahvi\u010dky v chladni\u010dce p\u0159i teplot\u011b 2\u20138 \u00b0C. Pro v\u00fdrazn\u011b dlouhodob\u011bj\u0161\u00ed skladov\u00e1n\u00ed lze neotev\u0159en\u00e9 lahvi\u010dky uchov\u00e1vat tak\u00e9 zmrazen\u00e9. Zabra\u0148te zbyte\u010dn\u00e9mu st\u0159\u00edd\u00e1n\u00ed teplot.<\/p>\n<p><strong>Jak by m\u011bl b\u00fdt tirzepatid skladov\u00e1n po rekonstituci?<\/strong><\/p>\n<p>Po rekonstituci je nutn\u00e9 roztok uchov\u00e1vat v chladni\u010dce p\u0159i teplot\u011b 2\u20138 \u00b0C a chr\u00e1nit jej p\u0159ed zbyte\u010dn\u00fdmi teplotn\u00edmi v\u00fdkyvy. Je t\u0159eba se vyhnout opakovan\u00fdm cykl\u016fm zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed.<\/p>\n<p><strong>M\u011bl by se tirzepatid b\u011bhem rekonstituce t\u0159\u00e1st?<\/strong><\/p>\n<p>Nen\u00ed nutn\u00e9 prov\u00e1d\u011bt prudk\u00e9 t\u0159ep\u00e1n\u00ed. P\u0159i rekonstituci peptid\u016f je vhodn\u011bj\u0161\u00ed \u0161etrn\u00e1 manipulace, zejm\u00e9na pokud je rozpou\u0161t\u011bn\u00ed pozvoln\u00e9, aby se minimalizovalo p\u011bn\u011bn\u00ed a zbyte\u010dn\u00fd mechanick\u00fd stres.<\/p>\n<p><strong>Pro\u010d se tirzepatid naz\u00fdv\u00e1 du\u00e1ln\u00ed agonista?<\/strong><\/p>\n<p>Tirzepatid je popisov\u00e1n jako du\u00e1ln\u00ed agonista, proto\u017ee jedin\u00e1 molekula aktivuje dva syst\u00e9my inkretinov\u00fdch receptor\u016f \u2013 GIP a GLP-1. To je v kontrastu s <a href=\"https:\/\/life-peptide.com\/cs\/product\/semaglutide-10-mg\/\">Semaglutid<\/a>\u2018aktivita GLP-1 receptoru a <a href=\"https:\/\/life-peptide.com\/cs\/product\/retatrutide-10-mg\/\">Retatrutid<\/a>\u2018\u0161ir\u0161\u00ed profil trojit\u00e9ho agonisty GLP-1\/GIP\/glukagonu.<\/p>\n<p><strong>Lze v Evrop\u011b koupit tirzepatid?<\/strong><\/p>\n<p>Ano. Tirzepatid zas\u00edl\u00e1me do v\u011bt\u0161iny evropsk\u00fdch zem\u00ed prost\u0159ednictv\u00edm spolehliv\u00fdch kur\u00fdrn\u00edch slu\u017eeb. Dostupn\u00e9 zp\u016fsoby dopravy a dodac\u00ed lh\u016fty se zobrazi b\u011bhem dokon\u010den\u00ed objedn\u00e1vky na z\u00e1klad\u011b va\u0161\u00ed c\u00edlov\u00e9 destinace.<\/p>\n<p><strong>Je tento produkt ur\u010den k lidsk\u00e9mu pou\u017eit\u00ed?<\/strong><\/p>\n<p>Ne. Tento produkt je dod\u00e1v\u00e1n v\u00fdhradn\u011b pro v\u00fdzkumn\u00e9 \u00fa\u010dely a nen\u00ed ur\u010den k lidsk\u00e9 spot\u0159eb\u011b ani k terapeutick\u00e9mu pou\u017eit\u00ed.<\/p>\n<hr \/>\n<h4><strong>Souvisej\u00edc\u00ed v\u00fdzkumn\u00fd kontext<\/strong><\/h4>\n<p>Tirzepatid je sou\u010d\u00e1st\u00ed t\u0159\u00eddy metabolick\u00e9ho v\u00fdzkumu du\u00e1ln\u00edch agonist\u016f inkretinov\u00fdch receptor\u016f (GLP-1\/GIP). Pro mechanistick\u00e9 porovn\u00e1n\u00ed s jednodruhov\u00fdmi agonisty GLP-1 a trojit\u00fdmi agonistick\u00fdmi slou\u010deninami viz na\u0161e <strong><a href=\"http:\/\/example.test\/glp-1-metabolic-research-guide\/\" target=\"_blank\" rel=\"noopener\">Pr\u016fvodce v\u00fdzkumem metabolismu GLP-1<\/a>.<\/strong><\/p>\n<p>Proch\u00e1zet v\u0161echny slou\u010deniny v <a href=\"\/cs\/product-category\/metabolic-research\/\"><strong>Kategorie metabolick\u00e9ho v\u00fdzkumu.<\/strong><\/a><\/p>\n<p>V\u00fdzkumn\u00edci porovn\u00e1vaj\u00edc\u00ed aktivaci v\u00edce receptor\u016f mohou tak\u00e9 zkoumat:<\/p>\n<ul>\n<li data-start=\"2635\" data-end=\"2671\"><a href=\"http:\/\/example.test\/product\/retatrutide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Retatrutid (trojit\u00fd agonistick\u00fd receptor pro GLP-1\/GIP\/glukagon)<\/a><\/li>\n<li data-start=\"2674\" data-end=\"2702\"><a href=\"http:\/\/example.test\/product\/semaglutide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Semaglutid (agonista receptoru GLP-1)<\/a><\/li>\n<\/ul>\n<p>Podrobn\u00e9 srovn\u00e1n\u00ed aktivity receptor\u016f, publikovan\u00fdch klinick\u00fdch zji\u0161t\u011bn\u00ed a v\u00fdzkumn\u00fdch rozd\u00edl\u016f si m\u016f\u017eete p\u0159e\u010d\u00edst v na\u0161em <a href=\"https:\/\/life-peptide.com\/cs\/retatrutide-vs-tirzepatide\/\">Porovn\u00e1n\u00ed v\u00fdzkumu retatrutidu a tirzepatidu<\/a>.<\/p>\n<p><strong>POZN\u00c1MKA:<\/strong> Tento text slou\u017e\u00ed pouze pro vzd\u011bl\u00e1vac\u00ed \u00fa\u010dely a nep\u0159edstavuje l\u00e9ka\u0159skou pomoc.<\/p>\n<p><strong>Upozorn\u011bn\u00ed:<\/strong><br \/>\nTento produkt je prod\u00e1v\u00e1n pouze pro v\u00fdzkumn\u00e9 \u00fa\u010dely. Nen\u00ed ur\u010den k diagnostice, l\u00e9\u010db\u011b, vyl\u00e9\u010den\u00ed nebo prevenci jak\u00fdchkoli onemocn\u011bn\u00ed. Kupuj\u00edc\u00ed p\u0159eb\u00edr\u00e1 plnou odpov\u011bdnost za \u0159\u00e1dnou manipulaci a pou\u017eit\u00ed.<\/p>","protected":false},"excerpt":{"rendered":"<p>Tirzepatid je du\u00e1ln\u00ed inkretinov\u00fd agonista ve v\u00fdzkumn\u00e9 kvalit\u011b dod\u00e1van\u00fd v lyofilizovan\u00e9 form\u011b pro laboratorn\u00ed pou\u017eit\u00ed. P\u016fsob\u00ed na receptory GLP-1 i GIP a stal se kl\u00ed\u010dovou referen\u010dn\u00ed slou\u010deninou v metabolismu, zejm\u00e9na v modelech regulace chuti k j\u00eddlu, zm\u011bn t\u011blesn\u00e9 hmotnosti, glykemick\u00e9 kontroly a inkretinov\u00e9 signalizace.<\/p>\n<p>||<\/p>\n<p>\u010cistota \u226599% | N\u00e1kup v Evrop\u011b s dopravou od 5 \u20ac | Mo\u017enost volby dopravy zdarma | P\u0159ij\u00edm\u00e1me platby kartou<\/p>","protected":false},"featured_media":1247,"template":"","meta":[],"product_brand":[],"product_cat":[19],"product_tag":[257,144,279,139,250,251,247,258,252,246],"class_list":["post-309","product","type-product","status-publish","has-post-thumbnail","product_cat-metabolic-research-peptides","product_tag-appetite-regulation","product_tag-dual-agonist","product_tag-fat-loss-peptide","product_tag-glp-1-research","product_tag-glp-1-gip-agonist","product_tag-glucose-research","product_tag-metabolic-peptide","product_tag-obesity-peptide","product_tag-obesity-research","product_tag-weight-loss-peptide","first","instock","taxable","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"_links":{"self":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product\/309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/media\/1247"}],"wp:attachment":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/media?parent=309"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product_brand?post=309"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product_cat?post=309"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product_tag?post=309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}